The Burning Question: To Use or Not to Use Cyclophosphamide in Systemic Sclerosis

Overview

Journal Eur J Rheumatol

Publisher Aves

Specialty Rheumatology

Date 2020 Nov 9

PMID 33164737

Citations 7

Authors

Cosimo Bruni

Daniel E Furst

Affiliations

Soon will be listed here.

Abstract

Fibrosis, inflammation, and vasculopathy are the main determinants of systemic sclerosis (SSc) pathogenesis. Cyclophosphamide (CYC), an alkylating agent, has been used to treat skin fibrosis and interstitial lung diseases in SSc for many years and still represents a mainstay in hematopoietic stem cell transplantation. Despite significant effect in reducing lung functional impairment and skin tightness, CYC has a significant safety burden, including infection risk and bone marrow and bladder toxicity. Moreover, it can affect fertility and also cause a predisposition for cancer development in the future, particularly in the bladder. This review summarizes the current evidences regarding the use of CYC to treat SSc, its efficacy and safety profile, and currently available or tested alternative drugs for lung and skin involvement in SSc.

Citing Articles

Autologous Hematopoietic Cell Transplant as an Effective Treatment Modality for Systemic Sclerosis and Multiple Myeloma.

Memon H, Parrondo R, Schreurs J, Ayala E, Iqbal M J Blood Med. 2025; 16():7-13.

PMID: 39802914 PMC: 11720633. DOI: 10.2147/JBM.S489627.

Clinical analysis of multiple primary gastrointestinal malignant tumors: A 10-year case review of a single-center.

Zhu C, Peng L World J Gastrointest Oncol. 2024; 16(4):1204-1212.

PMID: 38660651 PMC: 11037063. DOI: 10.4251/wjgo.v16.i4.1204.

Systemic Sclerosis Association with Malignancy.

Lepri G, Catalano M, Bellando-Randone S, Pillozzi S, Giommoni E, Giorgione R Clin Rev Allergy Immunol. 2022; 63(3):398-416.

PMID: 36121543 PMC: 9674744. DOI: 10.1007/s12016-022-08930-4.

Reproductive Issues and Pregnancy Implications in Systemic Sclerosis.

Lazzaroni M, Crisafulli F, Moschetti L, Semeraro P, Cunha A, Neto A Clin Rev Allergy Immunol. 2022; 64(3):321-342.

PMID: 35040084 DOI: 10.1007/s12016-021-08910-0.

Pharmacotherapy for the Treatment of Gastric Antral Vascular Ectasia: A Narrative Review.

Peng M, Guo X, Yi F, Romeiro F, Mancuso A, Qi X Adv Ther. 2021; 38(10):5065-5077.

PMID: 34524644 DOI: 10.1007/s12325-021-01912-6.

References

Furst D, Tseng C, Clements P, Strange C, Tashkin D, Roth M . Adverse events during the Scleroderma Lung Study. Am J Med. 2011; 124(5):459-67. DOI: 10.1016/j.amjmed.2010.12.009. View

van Laar J, Farge D, Sont J, Naraghi K, Marjanovic Z, Larghero J . Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014; 311(24):2490-8. DOI: 10.1001/jama.2014.6368. View

Bruni C, Shirai Y, Kuwana M, Matucci-Cerinic M . Cyclophosphamide: similarities and differences in the treatment of SSc and SLE. Lupus. 2019; 28(5):571-574. DOI: 10.1177/0961203319840433. View

Tashkin D, Roth M, Clements P, Furst D, Khanna D, Kleerup E . Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016; 4(9):708-719. PMC: 5014629. DOI: 10.1016/S2213-2600(16)30152-7. View

Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F . Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol. 2016; 13(5):469-482. DOI: 10.1080/1744666X.2017.1263153. View

Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho J . Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019; 78(7):979-987. DOI: 10.1136/annrheumdis-2018-214816. View

Gargani L, Todiere G, Guiducci S, Bruni C, Pingitore A, De Marchi D . Early Detection of Cardiac Involvement in Systemic Sclerosis: The Added Value of Magnetic Resonance Imaging. JACC Cardiovasc Imaging. 2018; 12(5):927-928. DOI: 10.1016/j.jcmg.2018.09.025. View

Shouval R, Furie N, Raanani P, Nagler A, Gafter-Gvili A . Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2018; 24(5):937-944. DOI: 10.1016/j.bbmt.2018.01.020. View

Volkmann E, Tashkin D, Sim M, Li N, Khanna D, Roth M . Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. J Rheumatol. 2019; 46(10):1316-1325. PMC: 6697251. DOI: 10.3899/jrheum.180441. View

10.

Matsumoto Y, Hayashi H, Tahara K, Yasuda T, Tsubouchi S, Yamamoto Y . Intravenous Cyclophosphamide for Gastric Antral Vascular Ectasia Associated with Systemic Sclerosis Refractory to Endoscopic Treatment: A Case Report and Review of the Pertinent Literature. Intern Med. 2018; 58(1):135-139. PMC: 6367100. DOI: 10.2169/internalmedicine.1431-18. View

11.

Herrick A, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L . Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017; 76(7):1207-1218. PMC: 5530354. DOI: 10.1136/annrheumdis-2016-210503. View

12.

Goldin J, Kim G, Tseng C, Volkmann E, Furst D, Clements P . Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. Ann Am Thorac Soc. 2018; 15(11):1286-1295. PMC: 6322015. DOI: 10.1513/AnnalsATS.201802-079OC. View

13.

Daoussis D, Liossis S, Tsamandas A, Kalogeropoulou C, Kazantzi A, Sirinian C . Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2009; 49(2):271-80. PMC: 2806066. DOI: 10.1093/rheumatology/kep093. View

14.

Bruni C, Cuomo G, Rossi F, Praino E, Bellando-Randone S . Kidney involvement in systemic sclerosis: From pathogenesis to treatment. J Scleroderma Relat Disord. 2022; 3(1):43-52. PMC: 8892882. DOI: 10.1177/2397198318758607. View

15.

Namas R, Tashkin D, Furst D, Wilhalme H, Tseng C, Roth M . Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2017; 70(3):439-444. PMC: 5700860. DOI: 10.1002/acr.23282. View

16.

Volkmann E, Tashkin D, Li N, Roth M, Khanna D, Hoffmann-Vold A . Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol. 2017; 69(7):1451-1460. PMC: 5560126. DOI: 10.1002/art.40114. View

17.

Massenkeil G, Alexander T, Rosen O, Dorken B, Burmester G, Radbruch A . Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation. Rheumatol Int. 2016; 36(11):1563-1568. DOI: 10.1007/s00296-016-3531-2. View

18.

Harward L, Mitchell K, Pieper C, Copland S, Criscione-Schreiber L, Clowse M . The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus. 2012; 22(1):81-6. DOI: 10.1177/0961203312468624. View

19.

Sullivan K, Goldmuntz E, Keyes-Elstein L, McSweeney P, Pinckney A, Welch B . Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018; 378(1):35-47. PMC: 5846574. DOI: 10.1056/nejmoa1703327. View

20.

Shreiner A, Murray C, Denton C, Khanna D . Gastrointestinal Manifestations of Systemic Sclerosis. J Scleroderma Relat Disord. 2017; 1(3):247-256. PMC: 5267349. DOI: 10.5301/jsrd.5000214. View